Repaglinide HCl | CAS# 135062-02-1 |

MedKoo Cat#: 591364 | Name: Repaglinide HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983.

Chemical Structure

Repaglinide HCl

CAS# 135062-02-1

Theoretical Analysis

MedKoo Cat#: 591364

Name: Repaglinide HCl

CAS#: 135062-02-1

Chemical Formula: C27H37ClN2O4

Exact Mass: 452.2675

Molecular Weight: 489.05

Elemental Analysis: C, 66.31; H, 7.63; Cl, 7.25; N, 5.73; O, 13.09

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Repaglinide; Prandin; Reglin; Repaglinide HCl; Repaglinide hydrochloride

IUPAC/Chemical Name

(+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid hydrochloride

InChi Key

HEZILSRDSMIVIQ-BQAIUKQQSA-N

InChi Code

InChI=1S/C27H36N2O4.ClH/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29;/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32);1H/t23-;/m0./s1

SMILES Code

O=C(O)C1=CC=C(CC(N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)=O)C=C1OCC.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 489.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wang Q, Rao HY, Yu N, Gao SQ, Wei L. [Comorbidities and concomitant medication use in adult patients with chronic hepatitis C: a descriptive epidemiological analysis]. Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):225-232. doi: 10.3760/cma.j.issn.1007-3418.2018.03.011. Chinese. PubMed PMID: 29804396. 2: Alam MS, Ahad A, Abidin L, Aqil M, Mir SR, Mujeeb M. Embelin-loaded oral niosomes ameliorate streptozotocin-induced diabetes in Wistar rats. Biomed Pharmacother. 2018 Jan;97:1514-1520. doi: 10.1016/j.biopha.2017.11.073. Epub 2017 Nov 20. PubMed PMID: 29793314. 3: Ishii Y, Ito Y, Matsuki S, Sanpei K, Ogawa O, Takeda K, Schuck EL, Uemura N. Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects. Clin Transl Sci. 2018 May 16. doi: 10.1111/cts.12557. [Epub ahead of print] PubMed PMID: 29768713. 4: Gosho M. Risk of Hypoglycemia After Concomitant Use of Antidiabetic, Antihypertensive, and Antihyperlipidemic Medications: A Database Study. J Clin Pharmacol. 2018 May 15. doi: 10.1002/jcph.1147. [Epub ahead of print] PubMed PMID: 29762878. 5: Pei Q, Liu JY, Yin JY, Yang GP, Liu SK, Zheng Y, Xie P, Guo CX, Luo M, Zhou HH, Li X, Liu ZQ. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population. Eur J Clin Pharmacol. 2018 May 11. doi: 10.1007/s00228-018-2477-6. [Epub ahead of print] PubMed PMID: 29748863. 6: Purna Chander C, Raju B, Ramesh M, Shankar G, Srinivas R. LC-ESI-MS/MS study of repaglinide and its forced degradation products. Rapid Commun Mass Spectrom. 2018 May 3. doi: 10.1002/rcm.8151. [Epub ahead of print] PubMed PMID: 29723439. 7: de Bruyn T, Ufuk A, Cantrill C, Kosa RE, Bi YA, Niosi M, Modi S, Rodrigues AD, Tremaine LM, Varma MV, Galetin A, Houston JB. Predicting Human Clearance of OATP substrates using Cynomolgus monkey: In vitro-in vivo scaling of hepatic uptake clearance. Drug Metab Dispos. 2018 May 2. pii: dmd.118.081315. doi: 10.1124/dmd.118.081315. [Epub ahead of print] PubMed PMID: 29720472. 8: Shang Z, Han F, Zhou X, Bao Z, Zhu J, Wang T, Lu Q, Du L, Li W, Lv D, Yin X. A variant of GRK5 is associated with the therapeutic efficacy of repaglinide in Chinese Han patients with type 2 diabetes mellitus. Drug Dev Res. 2018 May;79(3):129-135. doi: 10.1002/ddr.21426. Epub 2018 Apr 16. PubMed PMID: 29663513. 9: Cho HY, Ngo L, Kim SK, Choi Y, Lee YB. Bioequivalence of a fixed-dose repaglinide/metformin combination tablet and equivalent doses of repaglinide and metformin tablets. Int J Clin Pharmacol Ther. 2018 Jun;56(6):292-300. doi: 10.5414/CP203199. PubMed PMID: 29648532. 10: Takahashi H, Hidaka S, Seki C, Yokoi N, Seino S. Characteristics of repaglinide effects on insulin secretion. Eur J Pharmacol. 2018 Jun 5;828:52-59. doi: 10.1016/j.ejphar.2018.03.025. Epub 2018 Mar 16. PubMed PMID: 29555503. 11: López-Hurtado A, Burgos DF, González P, Dopazo XM, González V, Rábano A, Mellström B, Naranjo JR. Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease. Mol Brain. 2018 Mar 9;11(1):13. doi: 10.1186/s13041-018-0359-6. PubMed PMID: 29523177; PubMed Central PMCID: PMC5845147. 12: Rodriguez-Poncelas A, Barrot-de la-Puente J, Coll de Tuero G, López-Arpí C, Vlacho B, Lopéz-Simarro F, Mundet Tudurí X, Franch-Nadal J. Glycaemic control and treatment of type 2 diabetes in adults aged 75 years or older. Int J Clin Pract. 2018 Mar;72(3):e13075. doi: 10.1111/ijcp.13075. Epub 2018 Mar 7. PubMed PMID: 29512235. 13: Huguet J, Gaudette F, Michaud V, Turgeon J. Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes. Xenobiotica. 2018 Mar 8:1-13. doi: 10.1080/00498254.2018.1438684. [Epub ahead of print] PubMed PMID: 29448869. 14: Harrison J, De Bruyn T, Darwich AS, Houston JB. Simultaneous Assessment In Vitro of Transporter and Metabolic Processes in Hepatic Drug Clearance: Use of a Media Loss Approach. Drug Metab Dispos. 2018 Apr;46(4):405-414. doi: 10.1124/dmd.117.079590. Epub 2018 Feb 8. PubMed PMID: 29439129. 15: Doki K, Darwich AS, Achour B, Tornio A, Backman JT, Rostami-Hodjegan A. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide. Br J Clin Pharmacol. 2018 May;84(5):972-986. doi: 10.1111/bcp.13533. Epub 2018 Mar 6. PubMed PMID: 29381228; PubMed Central PMCID: PMC5903242. 16: Abo-Elseoud WS, Hassan ML, Sabaa MW, Basha M, Hassan EA, Fadel SM. Chitosan nanoparticles/cellulose nanocrystals nanocomposites as a carrier system for the controlled release of repaglinide. Int J Biol Macromol. 2018 May;111:604-613. doi: 10.1016/j.ijbiomac.2018.01.044. Epub 2018 Jan 9. PubMed PMID: 29325745. 17: Ballmann M, Hubert D, Assael BM, Staab D, Hebestreit A, Naehrlich L, Nickolay T, Prinz N, Holl RW; CFRD Study Group. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018 Feb;6(2):114-121. doi: 10.1016/S2213-8587(17)30400-X. Epub 2017 Dec 5. PubMed PMID: 29199116. 18: Leonard CE, Han X, Brensinger CM, Bilker WB, Cardillo S, Flory JH, Hennessy S. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):9-18. doi: 10.1002/pds.4337. Epub 2017 Nov 6. PubMed PMID: 29108130; PubMed Central PMCID: PMC5770147. 19: Wang SL, Dong WB, Dong XL, Zhu WM, Wang FF, Han F, Yan X. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget. 2017 Aug 16;8(42):72700-72713. doi: 10.18632/oncotarget.20282. eCollection 2017 Sep 22. PubMed PMID: 29069819; PubMed Central PMCID: PMC5641162. 20: Scheen AJ, Paquot N. [Use of oral glucose-lowering agents in patients with renal impairment]. Rev Med Liege. 2017 Oct;72(10):462-468. French. PubMed PMID: 29058840.